Cargando…
Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma
BACKGROUND: We performed subgroup analyses of the AFTER I-O study to clarify the association of time-to-treatment failure (TTF) and discontinuation reason of prior immune-oncology (I-O) therapy, and molecular targeted therapy (TT) regimen with the outcomes of TT after I-O. METHODS: The data of Japan...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558912/ https://www.ncbi.nlm.nih.gov/pubmed/34350454 http://dx.doi.org/10.1093/jjco/hyab114 |
_version_ | 1784592662557360128 |
---|---|
author | Tomita, Yoshihiko Kimura, Go Fukasawa, Satoshi Numakura, Kazuyuki Sugiyama, Yutaka Yamana, Kazutoshi Naito, Sei Kaneko, Hirokazu Tajima, Yohei Oya, Mototsugu |
author_facet | Tomita, Yoshihiko Kimura, Go Fukasawa, Satoshi Numakura, Kazuyuki Sugiyama, Yutaka Yamana, Kazutoshi Naito, Sei Kaneko, Hirokazu Tajima, Yohei Oya, Mototsugu |
author_sort | Tomita, Yoshihiko |
collection | PubMed |
description | BACKGROUND: We performed subgroup analyses of the AFTER I-O study to clarify the association of time-to-treatment failure (TTF) and discontinuation reason of prior immune-oncology (I-O) therapy, and molecular targeted therapy (TT) regimen with the outcomes of TT after I-O. METHODS: The data of Japanese metastatic renal cell carcinoma patients treated with TT after nivolumab (NIVO) (CheckMate 025) or NIVO + ipilimumab (IPI) (CheckMate 214) were retrospectively analyzed. The objective response rates (ORRs), progression-free survival (PFS) and overall survival (OS) of TT after I-O were analyzed by subgroups: TTF (<6 or ≥6 months) and discontinuation reason of prior I-O (progression or adverse events), and TT regimen (sunitinib or axitinib). We also analyzed PFS2 of prior I-O and OS from first-line therapy. RESULTS: The ORR and median PFS of TT after NIVO and NIVO+IPI among the subgroups was 17–36% and 20–44%, and 7.1–11.6 months and 16.3-not reached (NR), respectively. The median OS of TT after NIVO was longer in patients with longer TTF of NIVO and treated with axitinib. Conversely, median OS of TT after NIVO+IPI was similar among subgroups. The median PFS2 of NIVO and NIVO+IPI was 36.7 and 32.0 months, respectively. The median OS from first-line therapy was 70.5 months for patients treated with NIVO and NR with NIVO+IPI. The safety profile of each TT after each I-O was similar to previous reports. CONCLUSIONS: The efficacy of TT after NIVO or NIVO+IPI was favorable regardless of the TTF and discontinuation reason of prior I-O, and TT regimen. |
format | Online Article Text |
id | pubmed-8558912 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-85589122021-11-02 Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma Tomita, Yoshihiko Kimura, Go Fukasawa, Satoshi Numakura, Kazuyuki Sugiyama, Yutaka Yamana, Kazutoshi Naito, Sei Kaneko, Hirokazu Tajima, Yohei Oya, Mototsugu Jpn J Clin Oncol Original Article BACKGROUND: We performed subgroup analyses of the AFTER I-O study to clarify the association of time-to-treatment failure (TTF) and discontinuation reason of prior immune-oncology (I-O) therapy, and molecular targeted therapy (TT) regimen with the outcomes of TT after I-O. METHODS: The data of Japanese metastatic renal cell carcinoma patients treated with TT after nivolumab (NIVO) (CheckMate 025) or NIVO + ipilimumab (IPI) (CheckMate 214) were retrospectively analyzed. The objective response rates (ORRs), progression-free survival (PFS) and overall survival (OS) of TT after I-O were analyzed by subgroups: TTF (<6 or ≥6 months) and discontinuation reason of prior I-O (progression or adverse events), and TT regimen (sunitinib or axitinib). We also analyzed PFS2 of prior I-O and OS from first-line therapy. RESULTS: The ORR and median PFS of TT after NIVO and NIVO+IPI among the subgroups was 17–36% and 20–44%, and 7.1–11.6 months and 16.3-not reached (NR), respectively. The median OS of TT after NIVO was longer in patients with longer TTF of NIVO and treated with axitinib. Conversely, median OS of TT after NIVO+IPI was similar among subgroups. The median PFS2 of NIVO and NIVO+IPI was 36.7 and 32.0 months, respectively. The median OS from first-line therapy was 70.5 months for patients treated with NIVO and NR with NIVO+IPI. The safety profile of each TT after each I-O was similar to previous reports. CONCLUSIONS: The efficacy of TT after NIVO or NIVO+IPI was favorable regardless of the TTF and discontinuation reason of prior I-O, and TT regimen. Oxford University Press 2021-08-04 /pmc/articles/PMC8558912/ /pubmed/34350454 http://dx.doi.org/10.1093/jjco/hyab114 Text en © The Author(s) 2021. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Tomita, Yoshihiko Kimura, Go Fukasawa, Satoshi Numakura, Kazuyuki Sugiyama, Yutaka Yamana, Kazutoshi Naito, Sei Kaneko, Hirokazu Tajima, Yohei Oya, Mototsugu Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma |
title | Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma |
title_full | Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma |
title_fullStr | Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma |
title_full_unstemmed | Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma |
title_short | Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma |
title_sort | subgroup analysis of the after i-o study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in japanese patients with metastatic renal cell carcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558912/ https://www.ncbi.nlm.nih.gov/pubmed/34350454 http://dx.doi.org/10.1093/jjco/hyab114 |
work_keys_str_mv | AT tomitayoshihiko subgroupanalysisoftheafteriostudyaretrospectivestudyontheefficacyandsafetyofsubsequentmoleculartargetedtherapyafterimmuneoncologytherapyinjapanesepatientswithmetastaticrenalcellcarcinoma AT kimurago subgroupanalysisoftheafteriostudyaretrospectivestudyontheefficacyandsafetyofsubsequentmoleculartargetedtherapyafterimmuneoncologytherapyinjapanesepatientswithmetastaticrenalcellcarcinoma AT fukasawasatoshi subgroupanalysisoftheafteriostudyaretrospectivestudyontheefficacyandsafetyofsubsequentmoleculartargetedtherapyafterimmuneoncologytherapyinjapanesepatientswithmetastaticrenalcellcarcinoma AT numakurakazuyuki subgroupanalysisoftheafteriostudyaretrospectivestudyontheefficacyandsafetyofsubsequentmoleculartargetedtherapyafterimmuneoncologytherapyinjapanesepatientswithmetastaticrenalcellcarcinoma AT sugiyamayutaka subgroupanalysisoftheafteriostudyaretrospectivestudyontheefficacyandsafetyofsubsequentmoleculartargetedtherapyafterimmuneoncologytherapyinjapanesepatientswithmetastaticrenalcellcarcinoma AT yamanakazutoshi subgroupanalysisoftheafteriostudyaretrospectivestudyontheefficacyandsafetyofsubsequentmoleculartargetedtherapyafterimmuneoncologytherapyinjapanesepatientswithmetastaticrenalcellcarcinoma AT naitosei subgroupanalysisoftheafteriostudyaretrospectivestudyontheefficacyandsafetyofsubsequentmoleculartargetedtherapyafterimmuneoncologytherapyinjapanesepatientswithmetastaticrenalcellcarcinoma AT kanekohirokazu subgroupanalysisoftheafteriostudyaretrospectivestudyontheefficacyandsafetyofsubsequentmoleculartargetedtherapyafterimmuneoncologytherapyinjapanesepatientswithmetastaticrenalcellcarcinoma AT tajimayohei subgroupanalysisoftheafteriostudyaretrospectivestudyontheefficacyandsafetyofsubsequentmoleculartargetedtherapyafterimmuneoncologytherapyinjapanesepatientswithmetastaticrenalcellcarcinoma AT oyamototsugu subgroupanalysisoftheafteriostudyaretrospectivestudyontheefficacyandsafetyofsubsequentmoleculartargetedtherapyafterimmuneoncologytherapyinjapanesepatientswithmetastaticrenalcellcarcinoma |